March 3, 2026

Metformin does not significantly alter longitudinal dynamics of clonal hematopoiesis

Key Points

Clonal hematopoiesis growth rate showed a mild -0.06% per year reduction among metformin users, indicating modest effects.
Typical DNMT3A growth rates range from 5-7% annually, highlighting the small impact of metformin.
The analysis involved diabetic cohorts over a determined period, focusing on the longitudinal dynamics of clonal hematopoiesis.
Future prospective studies are needed to validate metformin's clinical utility for modifying clonal dynamics.

Abstract

In our cohorts, duration of metformin use among diabetic users was associated with a small reduction in CH growth rate (-0.06%/year), which is modest compared to typical DNMT3A clonal growth rates of 5-7% annually. Metformin's clinical utility for modulating clonal dynamics in real-world settings appear limited and its clinical use for this indication requires further investigation in prospective studies.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Pareek et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69a75d3bc6e9836116a26e7a — DOI: https://doi.org/10.1158/1078-0432.ccr-25-3606

Authors

Eshani Pareek

Yash Pershad

Kun Zhao

Journals

Clinical Cancer Research

Actions

Institutions

University of Washington

University of Michigan

Cornell University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Metformin does not significantly alter longitudinal dynamics of clonal hematopoiesis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion